Home > Cardiology > ESC 2022 > Polypill SECUREs win in secondary prevention in elderly

Polypill SECUREs win in secondary prevention in elderly

Presented By
Dr Valentin Fuster, Mount Sinai Health System, NY, USA
ESC 2022
Phase 3, SECURE
The 3-drug fixed-dose 'polypill' containing aspirin, ramipril, and atorvastatin, prevents secondary cardiovascular events in people ≥65 years old who have previously had a myocardial infarction, reducing cardiovascular mortality by 33% in this vulnerable patient population. Findings from the EU-funded, randomised, open-label SECURE trial (NCT02596126) were presented by Dr Valentin Fuster (Mount Sinai Health System, NY, USA), and simultaneously published in the New England Journal of Medicine [1,2]. It is the first trial testing the efficacy of a fixed-dose combination polypill for secondary cardiovascular prevention in individuals ≥65 years old. SECURE aimed to evaluate the potential benefit of the polypill as a component of a cost-effective, globally available, and comprehensive treatment strategy for secondary prevention of cardiovascular...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on